U.S. Stem Cell (USRM) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	5-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	BIOHEART, INC.
Entity Central Index Key	1388319
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		734,759,150

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$70,974	$36,674
Accounts receivable, net	78,489	95,409
Prepaid and other	258	9,255
Total current assets	149,721	141,338
Property and equipment, net	12,279	12,686
Other assets
Investments	49,563	40,597
Deposits	10,160	10,160
Total assets	221,723	204,781
Current liabilities:
Accounts payable	2,005,219	1,991,979
Accrued expenses	2,460,913	2,373,615
Advances, related party	148,759	148,759
Deferred revenue	39,233
Deposits	478,286	478,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	2,277,656	2,333,059
Notes payable, net of debt discount	1,538,607	1,531,812
Derivative liabilities	656,126	741,271
Total current liabilities	11,104,799	11,098,781
Commitments and contingencies
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 670,534,992 and 581,433,153 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	670,535	581,433
Additional paid in capital	109,909,100	108,939,061
Accumulated deficit	-121,482,711	-120,434,494
Total stockholders' deficit	-10,883,076	-10,894,000
Total liabilities and stockholders' deficit	$221,723	$204,781

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Balance Sheets [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	670,534,992	581,433,153
Common stock, shares outstanding	670,534,992	581,433,153

Condensed_Statements_of_Operat

Condensed Statements of Operations (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Products	$285,349	$233,636
Services	204,208	158,538
Total revenue	489,557	392,174
Cost and operating expenses:
Cost of sales	247,624	164,048
Research and development	50,145	9,857
Marketing, general and administrative	998,133	838,329
Depreciation and amortization	1,301	863
Total operating expenses	1,297,203	1,013,097
Net loss from operations	-807,646	-620,923
Other (expenses) income:
Gain on settlement of debt	59,430	2,093,632
Gain (loss) on change of fair value of derivative liability	122,724	-489,371
Income from equity investment	3,966
Other income	3,151
Interest expense	-429,842	-305,898
Total other (expenses) income	-240,571	1,298,363
Net (loss) income before income taxes	-1,048,217	677,440
Income taxes (benefit)
NET (LOSS) INCOME	($1,048,217)	$677,440
Net (loss) income per common share, basic	($0.00)	$0.00
Net (loss) income per common share, diluted	($0.00)	$0.00
Weighted average number of common shares outstanding, basic	626,644,025	401,553,577
Weighted average number of common shares outstanding, diluted	626,644,025	498,696,292

Condensed_Statement_of_Stockho

Condensed Statement of Stockholders' Deficit (unaudited) (USD $)	Total	Preferred stock	Common stock	Additional Paid in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2014	($10,894,000)	$20,000	$581,433	$108,939,061	($120,434,494)
Beginning Balance, Shares at Dec. 31, 2014		20,000,000	581,433,153
Common stock issued in settlement of accounts payable	41,782		4,784	36,998
Common stock issued in settlement of accounts payable, Shares			4,783,568
Common stock issued in connection with the conversion of debt	462,725		40,704	422,021
Common stock issued in connection with the conversion of debt, Shares			40,704,366
Proceeds from issuance of common stock	299,848		36,964	262,884
Proceeds from issuance of common stock, Shares			36,963,905
Common stock issued in settlement of litigation	59,850		6,650	53,200
Common stock issued in settlement of litigation, Shares			6,650,000
Stock based compensation	194,936			194,936
Net loss	-1,048,217				-1,048,217
Ending Balance at Mar. 31, 2015	($10,883,076)	$20,000	$670,535	$109,909,100	($121,482,711)
Ending Balance, Shares at Mar. 31, 2015		20,000,000	670,534,992

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	($1,048,217)	$677,440
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,301	863
Bad debt expense		10,000
Discount on convertible debt	231,795	93,604
Change in fair value of derivative liability	-122,724	489,371
Gain on settlement of debt	-59,430	-2,093,632
Loss on settlement of litigation	59,850
Non cash payment of interest	88,578	164,757
Warrants issued in connection with joint venture agreement		22,546
Income on equity investments	-3,966
Stock based compensation	194,936	194,564
(Increase) decrease in:
Receivables	16,920	-38,841
Prepaid and other current assets	8,997	-742
Increase (decrease) in:
Accounts payable	114,452	172,786
Accrued expenses	94,024	49,522
Deferred revenue	39,233
Net cash used in operating activities	-384,251	-257,762
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for investments	-5,000
Acquisitions of property and equipment	-894
Net cash used by investing activities	-5,894
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	299,848	371,000
Repayments of related party advances		-10,241
Proceeds from exercise of stock options and warrants		6,000
Proceeds from notes payable	180,000	127,500
Repayments of notes payable	-55,403	-63,740
Net cash provided in financing activities	424,445	430,519
Net increase in cash and cash equivalents	34,300	172,757
Cash and cash equivalents, beginning of period	36,674	46,227
Cash and cash equivalents, end of period	70,974	218,984
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	108,471	84,986
Income taxes paid
Non cash financing activities:
Common stock issued in connection with the conversion of debt	231,727	194,044
Common stock issued in settlement of accounts payable	$41,782	$107,475

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:
	General
	The accompanying unaudited condensed financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ended December 31, 2015. The unaudited condensed financial statements should be read in conjunction with the December 31, 2014 financial statements and notes thereto included in the Company’s Annual Report on Form 10-K.
	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.
	Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied.
	Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.
	At March 31, 2015 and December 31, 2014, the Company had deferred revenues of $39,233 and $-0-, respectively.
	Accounts Receivable
	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
	Allowance for Doubtful Accounts
	Any changes to the allowance for doubtful accounts on accounts receivable are changed to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of March 31, 2015 and 2014, allowance for doubtful accounts was $-0-.
	Investments
	The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Shares issuable upon conversion of convertible debt, stock options and warrants have been excluded as common stock equivalents in the diluted loss per share for the three months ended March 31, 2015 because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 649,121,525 and 498,696,292 for the three months ended March 31, 2015 and 2014, respectively.
	Stock based compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of March 31, 2015, there were outstanding stock options to purchase 73,900,497 shares of common stock, 31,789,510 shares of which were vested.
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
	As of March 31, 2015, three customers represented 16%, 16% and 23%, aggregate of 55% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, aggregate of 55%, of the Company’s accounts receivable.
	The Company’s revenues earned from sale of products and services for the three months ended March 31, 2015 did not include any concentrations. For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $50,145 and $9,857 for the three months ended March 31, 2015 and 2014, respectively.
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	At March 31, 2015, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9)
	Reliance on Key Personnel and Consultants
	The Company has four full-time employees and one part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Going_Concern_Matters

Going Concern Matters	3 Months Ended
	Mar. 31, 2015
Going Concern Matters [Abstract]
GOING CONCERN MATTERS	NOTE 2 — GOING CONCERN MATTERS
	The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during three months ended March 31, 2015, the Company incurred an operating loss of $1,048,217 and used $384,251 in cash for operating activities. As of March 31, 2015, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $11.0 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Investments

Investments	3 Months Ended
	Mar. 31, 2015
Investments [Abstract]
INVESTMENTS	NOTE 3 — INVESTMENTS
	Investment is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The initial investment in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf was in aggregate of $54,714. The Company’s 33% income earned by U.S. Stem Cell Clinic, LLC of $3,966 for the three months ended March 31, 2015 (inception to date loss of $5,151) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods and increased the carrying value of the investment to $49,563.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 — PROPERTY AND EQUIPMENT
	Property and equipment as of March 31, 2015 and December 31, 2014 summarized as follows:
		March 31,			December 31,
		2015			2014
	Laboratory and medical equipment	$	353,252		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		47,647			47,647
	Leasehold improvements		362,046			362,046
			888,579			887,685
	Less accumulated depreciation and amortization		(876,300	)		(874,999	)
		$	12,279		$	12,686
	Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.
	Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
ACCRUED EXPENSES	NOTE 5 — ACCRUED EXPENSES
	Accrued expenses consisted of the following as of March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,571,863		1,533,217
	Interest payable on notes payable		747,141		685,575
	Vendor accruals and other		127,114		120,836
	Employee commissions, compensation, etc.		14,795		33,987
		$	2,460,913	$	2,373,615
	During the three months ended March 31, 2014, the Company issued an aggregate of 6,750,781 shares of its common stock in settlement of outstanding accounts payable. In connection with the issuance, the Company incurred $65,548 loss in settlement of debt.
	For the three months ended March 31, 2015 the Company recognized a gain of $59,430 related to the settlement or write off of accounts payable and accrued expenses.

Stock_Purchase_Agreement

Stock Purchase Agreement	3 Months Ended
	Mar. 31, 2015
Stock Purchase Agreement [Abstract]
STOCK PURCHASE AGREEMENT	NOTE 6 – STOCK PURCHASE AGREEMENT
	On October 23, 2014, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Investor is committed to purchase up to $3,000,000 (the “Total Commitment”) worth of the Company’s common stock, $0.001 par value (the “Shares”), over the 24-month term of the Purchase Agreement.
	From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement is declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $0.0025 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”).
	The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “VWAP”) during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company’s common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
	In 2014, the Company paid to the Investor as a commitment fee for entering into the Purchase Agreement equal an aggregate of to 12,000,000 shares of the Company’s common stock.
	During the three months ended March 31, 2015, the Company issued an aggregate of 35,520,249 shares of its common stock in exchange for $283,578 under the stock purchase agreement.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 7 — NOTES PAYABLE
	Notes payable were comprised of the following as of March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Seaside Bank note payable.	$	980,000		$	980,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		190,000			151,000
	Daniel James Management note payable		75,000			75,000
	Fourth Man, LLC note payable		75,000			75,000
	Magna Group		130,000			205,000
	Total notes payable		1,834,972			1,870,972
	Less unamortized debt discount		(296,365	)		(339,160	)
	Total notes payable net of unamortized debt discount	$	1,538,607		$	1,531,812
	Seaside Bank
	On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.
	Hunton & Williams Notes
	At March 31, 2015 and December 31, 2014, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
	Asher Notes (During this period)
	During the three months ended March 31, 2015, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $114,000 (the “Asher Notes”). The Company incurred legal fees in the amount of $9,000 which were deducted from the proceeds of the notes.
	The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended March 31, 2015, all interest and principal must be repaid nine months from the issuance date, with the last note being due December 26, 2015. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.
	These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at March 31, 2015 was $124,260. At the inception of the Asher Notes, the Company determined the aggregate fair value of $137,764 of the embedded derivatives.
	During the three months ended March 31, 2015, $75,000 of notes that were outstanding at December 31, 2014, plus accrued interest were converted into shares of the Company’s common stock (see Note 10).
	The remaining aggregate Asher Notes unconverted principle balance as of March 31, 2015 was $190,000.
	Daniel James Management (During this period)
	During the three months ended March 31, 2015, the Company entered into a Securities Purchase Agreement with Daniel James Management (“Daniel”) for the sale of 9.5% convertible note in aggregate principal amount of $25,000 (the “Daniel Note”).
	The Daniel Note bears interest at the rate of 9.5% per annum. As of the quarter ended March 31, 2015, all interest and principal must be repaid one year from the issuance date, March 30, 2015. The Daniel Note is convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.
	The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Note and to fair value as of each subsequent reporting date which at March 31, 2015 was $32,972. At the inception of the Daniel Note, the Company determined the aggregate fair value of $35,551 of the embedded derivatives.
	During the three months ended March 31, 2015, $25,000 of notes that were outstanding at December 31, 2014, plus accrued interest were converted into shares of the Company’s common stock (see Note 10).
	The remaining aggregate Daniel James Management Notes unconverted principle balance as of March 31, 2015 was $75,000.
	Fourth Man, LLC (During this period)
	During the three months ended March 31, 2015, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”), for the sale of a 9.5% convertible notes in the aggregate principal amount of $50,000 (the “Note”).
	The Notes bears interest at the rate of 8% to 9.5% per annum. As of the quarter ended March 31, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due August 28, 2015. The Notes are convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision.
	The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at March 31, 2015 was $65,705. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $95,263 of the embedded derivatives.
	During the three months ended March 31, 2015, $50,000 of notes that were outstanding at December 31, 2014, plus accrued interest, were converted into shares of the Company’s common stock (see Note 10).
	The remaining aggregate Fourth Man, LLC Notes unconverted principle balance as of March 31, 2015 was $75,000.
	Magna Group (During this period)
	During the three months ended March 31, 2015, $75,000 of notes that were outstanding at December 31, 2014, plus accrued interest, were converted into shares of the Company’s common stock (see Note 10). The remaining aggregate Magna notes unconverted principle balance as of March 31, 2015 was $130,000.
	The fair value of the embedded derivatives of the Asher, Daniel and Fourth Man Notes, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 112.86% to 116.65%, (3) weighted average risk-free interest rate of 0.17% to 0.27%, (4) expected lives of 0.75 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.0089 to $0.0127 per share. The initial fair value of the embedded debt derivative of $268,578 was allocated as a debt discount up to the proceeds of the notes ($180,000) with the remainder ($88,578) charged to current period operations as interest expense. For the three months ended March 31, 2015 and 2014, the Company amortized an aggregate of $231,795 and $93,604 of debt discounts to current period operations as interest expense, respectively.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 — RELATED PARTY TRANSACTIONS
	Advances
	As of March 31, 2015 and December 31, 2014, the Company’s officers and directors have provided advances in the aggregate of $148,759 for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.
	Notes payable-related party
	Northstar Biotechnology Group, LLC
	On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.
	On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
	On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance.
	On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.
	In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
	Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.
	In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement.
	In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.
	As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013.
	On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.
	On December 24, 2013, the Company issued 3,915,662 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447.
	On April 2, 2014, the Company issued 274,681 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement.
	On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license.
	On October 3, 2014, the Company issued 514,886 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement.
	As of March 31, 2015 and December 31, 2014, the principle of this note was $362,000.
	Officer and Director Notes
		March 31,		December 31,
		2015		2014
	Notes payable, Dr Murphy	$	465,240	$	465,240
	Note payable, Mr. Tomas		280,143		331,354
	Note payable, Mr. Tomas		375,000		375,000
	Note payable, Mr. Tomas		500,000		500,000
	Note payable, Ms. Comella		295,273		299,465
	Total	$	1,915,656	$	1,971,059
	Notes payable, Dr. Murphy
	At March 31, 2015 and December 31, 2014, the Company has outstanding notes payable to Dr. Murphy with interest at 8% per annum due at maturity in aggregate $465,240. Of the outstanding balance, certain subordinated notes $100,000 and $140,000 were previously due on November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.
	Notes payable, Mr. Tomas
	In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bear interest of 5% per annum and due on demand. During the three months ended March 31, 2015, the Company paid off $51,211 of the outstanding promissory note. The principle outstanding balance of these notes as of March 31, 2015 is $280,143.
	On August 1, 2013, the Company issued a $375,000 promissory notes due on demand in settlement of accrued compensation. The promissory note bear interest of 5% per annum and due on demand. The principle outstanding balance of these notes as of March 31, 2015 is $375,000.
	On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due on January 1, 2015. The principle outstanding balance of these notes as of March 31, 2015 is $500,000.
	Notes payable, Ms. Comella
	On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due on January 1, 2015. During the three months ended March 31, 2015, the Company paid off $4,192 of the outstanding promissory note. The principle outstanding balance of these notes as of March 31, 2015 is $295,273.
	Subordinated debt, related party
	As of March 31, 2015 and December 31, 2014, the Company’s officers and directors have provided notes in aggregate of $1,500,000. The notes range from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.

Derivative_Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2015
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	NOTE 9 — DERIVATIVE LIABILITIES
	Reset warrants
	On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.
	The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.
	At March 31, 2015, the fair value of the reset provision related to the embedded derivative liability of $114,349 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 112.86%; risk free rate: 1.71%; and expected life: 7.50 years. The Company recorded a gain on change in derivative liabilities of $35,571 during the three months ended March 31, 2015.
	Convertible notes
	In 2014 and the three months ended March 31, 2015, the Company issued convertible notes (see Note 7 above).
	These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date.
	The fair value of the embedded derivatives at March 31, 2015, in the amount of $541,777, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 112.86%, (3) weighted average risk-free interest rate of 0.03 to 0.26%, (4) expected lives of 0.27 to 1.00 years, and (5) estimated fair value of the Company’s common stock of $0.089 per share. The Company recorded a gain on change in derivative liabilities of $87,153 during the three months ended March 31, 2015.
	Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 10 — STOCKHOLDERS’ EQUITY
	During the three months ended March 31, 2015, the Company issued an aggregate of 4,783,568 shares of its common stock in the amount of $41,782 for the settlement of outstanding accounts payable and accrued expenses. In connection with the issuance of the shares the Company recognized a gain on settlement of accounts payable and accrued expenses in the amount of $41,507 (see Note 5).
	During the three months ended March 31, 2015, the Company issued 6,650,000 shares of common stock in settlement of litigation. In connection with the issuances, the Company recognized a loss in the amount of $59,850, which is included in the marketing, general and administration expense in the Statement of Operations (see Note 12).
	During the three months ended March 31, 2015, the Company issued an aggregate of 40,704,366 shares of its common stock for the conversion of $231,727 of notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $230,999 (see Note 13).
	During the three months ended March 31, 2015, the Company issued an aggregate of 35,520,249 shares of common stock in exchange for $283,578 under the stock purchase agreement with Magna Equities II, LLC (see Note 6), and issued an aggregate of 1,443,656 shares of common stock in exchange for $16,270. In connection with the stock sale, the Company issued an aggregate of 1,443,656 warrants to purchase the Company’s common stock (see Note 11).

Stock_Options_and_Warrants

Stock Options and Warrants	3 Months Ended
	Mar. 31, 2015
Stock Options and Warrants [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE 11 — STOCK OPTIONS AND WARRANTS
	Stock Options
	In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.
	On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred million shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan.
	A summary of options at March 31, 2015 and activity during the three months then ended is presented below:
								Weighted-
								Average
					Weighted-			Remaining
					Average			Contractual
		Shares			Exercise Price			Term (in years)
	Options outstanding at January 1, 2014	23,912,943			$	0.15		9
	Granted	43,148,487			$	0.023		10
	Exercised	—			$
	Forfeited/Expired	(136,221	)		$	5.2
	Options outstanding at December 31, 2014	66,925,209			$	0.056		8.9
	Granted	7,000,000			$	0.01116		10
	Exercised	—
	Forfeited/Expired	(24,712	)		$	0.71
	Options outstanding at March 31, 2015	73,900,497			$	0.05147		8.8
	Options exercisable at March 31, 2015	31,789,510			$	0.09176		8.8
	Available for grant at March 31, 2015	89,500,000
	The following information applies to options outstanding and exercisable at March 31, 2015:
		Options Outstanding							Options Exercisable
				Weighted-
				Average		Weighted-				Weighted-
				Remaining		Average				Average
				Contractual		Exercise				Exercise
		Shares		Term		Price			Shares	Price
	$0.00 – $0.70	73,438,487		8.8		$	0.024		31,327,500	$	0.03
	$0.71 – $1.28	125,218		4.2		$	0.828		125,218	$	0.83
	$5.25 – $5.67	312,080		1.3		$	5.53		312,080	$	5.53
	$7.69	24,712		1.3		$	7.69		24,712	$	7.69
		73,900,497		8.8		$	0.05147		31,789,510	$	0.09176
	On February 2, 2015, the Company issued an aggregate 7,000,000 options to purchase the Company’s common stock at $0.01116 per share to board of directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $121,735, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 142.65% and Risk free rate: 1.68%.
	The fair value of all options vesting during the three months ended March 31, 2015 and 2014 of $196,966 and $194,564, respectively, was charged to current period operations.
	Warrants
	A summary of common stock purchase warrants at March 31, 2015 and activity during the period then ended is presented below:
								Weighted-
					Weighted-			Average
					Average			Remaining
					Exercise			Contractual
		Shares			Price			Term (in years)
	Outstanding at January 1, 2014	118,078,856			$	0.22		6.3
	Issued	57,582,469			$	0.02		8.2
	Exercised	(11,918,181	)		$	0.01
	Expired	(13,178,145	)		$	0.08
	Outstanding at December 31, 2014	150,564,999			$	0.17		6.6
	Issued	1,443,656			$	0.01127		10
	Exercised				$
	Expired	(1,233,334	)		$	0.0316
	Outstanding at March 31, 2015	150,775,321			$	0.169		6.5
	Exercisable at March 31, 2015	135,855,019			$	0.1		6.5
	The following information applies to common stock purchase warrants outstanding and exercisable at March 31, 2015:
		Warrants Outstanding							Warrants Exercisable
				Weighted-
				Average		Weighted-				Weighted-
				Remaining		Average				Average
				Contractual		Exercise				Exercise
		Shares		Term		Price			Shares	Price
	$0.01 – $0.50	144,526,188		6.5		$	0.02		131,150,336	$	0.02
	$0.52 – $0.68	2,699,675		4.1		$	0.58		2,699,675	$	0.58
	$0.70 – $1.62	848,176		4.8		$	0.71		848,176	$	0.71
	$5.67 – $7.69	2,701,282		7.6		$	7.55		1,156,832	$	7.35
		150,775,321		6.5		$	0.169		135,855,019	$	0.1
In conjunction with the authorized issuance of common stock, the Company granted 1,443,656 common stock purchase warrants during the three months ended March 31, 2015.

Commiments_and_Contingencies

Commiments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 — COMMITMENTS AND CONTINGENCIES
	Litigation
	On March 19 2015, the Company settled a prospective dispute with a third party over the use of proprietary information through the issuance of 6,650,000 shares of common stock.
	On November 10, 2014, the Company was served with a lawsuit by an alleged assignee and a guarantor to a Loan Guarantee, Payment and Security Agreement. These parties claim breach of that Agreement and damages of approximately $2.3 Million plus interest. The assignor and assignee also sued the Company’s directors and two past directors and an affiliate shareholder for breach of fiduciary duty, claiming damages as alleged creditors arising out of these parties’ alleged participation in Northstar Biotech Group, LLC, a secured creditor of the Company. Management recognizes that this lawsuit can divert managerial and financial resources, and, if there is an adverse outcome, unfavorably affect our financial condition, results of operations and stock price, but management believes the lawsuit is without merit and will defend the lawsuit vigorously.
	The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2015, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2015
Fair Value Measurement [Abstract]
FAIR VALUE MEASUREMENT	NOTE 13 — FAIR VALUE MEASUREMENT
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of March 31, 2015 or December 31, 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.
	As of March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	The derivative liability as of March 31, 2015, in the amount of $656,126 has a level 3 classification.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2015:
		Warrant			Debt
		Liability			Derivative
	Balance, December 31, 2013		146,855		$	256,956
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			1,443,708
	Initial fair value of derivative relating to reset warrants		—			—
	Mark-to-market at December 31, 2014:		3,065			(429,018	)
	Transfers out of Level 3 upon increase in authorized shares		—			—
	Transfers out of Level 3 upon conversion and settlement of notes		—			(680,295	)
	Balance, December 31, 2014	$	149,920		$	591,351
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			268,578
	Mark-to-market at March 31, 2015:		(35,571	)		(87,153	)
	Transfers out of Level 3 upon conversion or payoff of notes payable		—			(230,999	)
	Balance, March 31, 2015	$	114,349		$	541,777
	Net Gain for the period included in earnings relating to the
	liabilities held at March 31, 2015	$	35,571		$	87,153
	Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price decreased approximately 15% from December 31, 2014 to March 31, 2015. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.The estimated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 — SUBSEQUENT EVENTS
	Subsequent stock issuances
	On April 2, 2015, the Company issued 11,508,100 shares of common stock in settlement of $213,904 of accrued payables to Guarantor of the Company’s loan agreement with Bank of America and Seaside Bank. (See Note 5).
	In April 2015, the Company sold 540,736 shares of its common stock for net proceeds of $5,000. In connection with the stock sale, the Company issued 540,736 warrants to purchase the Company’s common stock for five years at $0.009247 per share. In In addition, the Company issued 6,869,151 shares of its common stock in settlement for services, provided, 22,053,009 shares of its common stock in settlement of $79,000 of outstanding convertible notes payable, and $2,739 accrued interest, 1,363,031 shares of its common stock in settlement of $12,635.29 related party interest on Northstar debt (see Note 8), 14,917,086 shares of our common stock in exchange of $79,075 draw down on the Magna equity line and on April 9, 2015, the Company issued 413,289 shares of its common stock in settlement as “true up” shares pursuant to the draw down on the equity line.
	Subsequent financing
	On April 13, 2015, the Company entered into a Securities Purchase Agreement with Vis Vires Group, Inc. (“Vis”), for the sale of an 8% convertible note in the principal amount of $33,000 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on January 16, 2016. The Note is convertible into common stock, at Vis’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owed multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
	On April 27, 2015, the Company entered into a Securities Purchase Agreement with Daniel James Management, Inc., for the sale of an 9.5% convertible note in the principal amount of $25,000 (the “Note”).
	The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on April 26, 2016. The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Basis and business presentation	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.
	Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied.
	Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.
	At March 31, 2015 and December 31, 2014, the Company had deferred revenues of $39,233 and $-0-, respectively.
Accounts Receivable	Accounts Receivable
	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts
	Any changes to the allowance for doubtful accounts on accounts receivable are changed to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of March 31, 2015 and 2014, allowance for doubtful accounts was $-0-.
Investments	Investments
	The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.
Comprehensive Income	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
Net loss per Common Share, basic and diluted	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Shares issuable upon conversion of convertible debt, stock options and warrants have been excluded as common stock equivalents in the diluted loss per share for the three months ended March 31, 2015 because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 649,121,525 and 498,696,292 for the three months ended March 31, 2015 and 2014, respectively.
Stock based compensation	Stock based compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of March 31, 2015, there were outstanding stock options to purchase 73,900,497 shares of common stock, 31,789,510 shares of which were vested.
Concentrations of Credit Risk	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
	As of March 31, 2015, three customers represented 16%, 16% and 23%, aggregate of 55% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, aggregate of 55%, of the Company’s accounts receivable.
	The Company’s revenues earned from sale of products and services for the three months ended March 31, 2015 did not include any concentrations. For the three months ended March 31, 2014, the Company’s revenues earned from the sale of products and services were $322,572, of which two customers represented 17% and 10% of the Company’s revenues.
Research and Development	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $50,145 and $9,857 for the three months ended March 31, 2015 and 2014, respectively.
Fair Value	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivative Instrument Liability	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	At March 31, 2015, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 9)
Reliance on Key Personnel and Consultants	Reliance on Key Personnel and Consultants
	The Company has four full-time employees and one part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Reclassification	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Shedule of notes payable-related party
		March 31,		December 31,
		2015		2014
	Notes payable, Dr Murphy	$	465,240	$	465,240
	Note payable, Mr. Tomas		280,143		331,354
	Note payable, Mr. Tomas		375,000		375,000
	Note payable, Mr. Tomas		500,000		500,000
	Note payable, Ms. Comella		295,273		299,465
	Total	$	1,915,656	$	1,971,059

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
Summary of property and equipment		March 31,			December 31,
		2015			2014
	Laboratory and medical equipment	$	353,252		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		47,647			47,647
	Leasehold improvements		362,046			362,046
			888,579			887,685
	Less accumulated depreciation and amortization		(876,300	)		(874,999	)
		$	12,279		$	12,686

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
Summary of accrued expenses		March 31,		December 31,
		2015		2014
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,571,863		1,533,217
	Interest payable on notes payable		747,141		685,575
	Vendor accruals and other		127,114		120,836
	Employee commissions, compensation, etc.		14,795		33,987
		$	2,460,913	$	2,373,615

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Summary of notes payable
		March 31,			December 31,
		2015			2014
	Seaside Bank note payable.	$	980,000		$	980,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		190,000			151,000
	Daniel James Management note payable		75,000			75,000
	Fourth Man, LLC note payable		75,000			75,000
	Magna Group		130,000			205,000
	Total notes payable		1,834,972			1,870,972
	Less unamortized debt discount		(296,365	)		(339,160	)
	Total notes payable net of unamortized debt discount	$	1,538,607		$	1,531,812

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Options and Warrants [Abstract]
Summary of options and activity
								Weighted-
								Average
					Weighted-			Remaining
					Average			Contractual
		Shares			Exercise Price			Term (in years)
	Options outstanding at January 1, 2014	23,912,943			$	0.15		9
	Granted	43,148,487			$	0.023		10
	Exercised	—			$
	Forfeited/Expired	(136,221	)		$	5.2
	Options outstanding at December 31, 2014	66,925,209			$	0.056		8.9
	Granted	7,000,000			$	0.01116		10
	Exercised	—
	Forfeited/Expired	(24,712	)		$	0.71
	Options outstanding at March 31, 2015	73,900,497			$	0.05147		8.8
	Options exercisable at March 31, 2015	31,789,510			$	0.09176		8.8
	Available for grant at March 31, 2015	89,500,000
Summary of options outstanding and exercisable for stock-based payment awards
		Options Outstanding							Options Exercisable
				Weighted-
				Average		Weighted-				Weighted-
				Remaining		Average				Average
				Contractual		Exercise				Exercise
		Shares		Term		Price			Shares	Price
	$0.00 – $0.70	73,438,487		8.8		$	0.024		31,327,500	$	0.03
	$0.71 – $1.28	125,218		4.2		$	0.828		125,218	$	0.83
	$5.25 – $5.67	312,080		1.3		$	5.53		312,080	$	5.53
	$7.69	24,712		1.3		$	7.69		24,712	$	7.69
		73,900,497		8.8		$	0.05147		31,789,510	$	0.09176
Summary of warrants and activity
								Weighted-
					Weighted-			Average
					Average			Remaining
					Exercise			Contractual
		Shares			Price			Term (in years)
	Outstanding at January 1, 2014	118,078,856			$	0.22		6.3
	Issued	57,582,469			$	0.02		8.2
	Exercised	(11,918,181	)		$	0.01
	Expired	(13,178,145	)		$	0.08
	Outstanding at December 31, 2014	150,564,999			$	0.17		6.6
	Issued	1,443,656			$	0.01127		10
	Exercised				$
	Expired	(1,233,334	)		$	0.0316
	Outstanding at March 31, 2015	150,775,321			$	0.169		6.5
	Exercisable at March 31, 2015	135,855,019			$	0.1		6.5
Summary of warrants outstanding and exercisable
		Warrants Outstanding							Warrants Exercisable
				Weighted-
				Average		Weighted-				Weighted-
				Remaining		Average				Average
				Contractual		Exercise				Exercise
		Shares		Term		Price			Shares	Price
	$0.01 – $0.50	144,526,188		6.5		$	0.02		131,150,336	$	0.02
	$0.52 – $0.68	2,699,675		4.1		$	0.58		2,699,675	$	0.58
	$0.70 – $1.62	848,176		4.8		$	0.71		848,176	$	0.71
	$5.67 – $7.69	2,701,282		7.6		$	7.55		1,156,832	$	7.35
		150,775,321		6.5		$	0.169		135,855,019	$	0.1

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Schedule of difference between income tax expenses
		2014				2013
	Income taxes using U.S. federal statutory rate	$	(766,194	)		$	(1,068,708	)
	State income taxes, net of federal benefit		(90,051	)			(108,788	)
	Stock Option Expirations		66,043				78,864
	Net Operating Loss adjustments		(144,824	)			(20,008	)
	Nontaxable Gain on Derivative Instrument		933,477				(9,921	)
	Change in Valuation Allowance		1,549				1,127,875
	Other						686
		$	-			$	—
Components of the deferred tax assets (liabilities)
		2014			2013
	Deferred tax assets:
	Stock Based Compensation	$	4,794,777		$	4,465,854
	Net Operating Losses		36,117,831			35,429,429
	Other		41,469			125,317
	Total deferred tax assets		40,954,077			40,020,600
	Deferred tax liabilities:		-			—
	Total deferred tax liabilities		-			—
	Valuation allowance		40,954,077			40,020,600
	Net deferred tax assets	$			$	—

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Measurement [Abstract]
Summary of changes in fair value of the Company's Level 3 financial liabilities
		Warrant			Debt
		Liability			Derivative
	Balance, December 31, 2013		146,855		$	256,956
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			1,443,708
	Initial fair value of derivative relating to reset warrants		—			—
	Mark-to-market at December 31, 2014:		3,065			(429,018	)
	Transfers out of Level 3 upon increase in authorized shares		—			—
	Transfers out of Level 3 upon conversion and settlement of notes		—			(680,295	)
	Balance, December 31, 2014	$	149,920		$	591,351
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			268,578
	Mark-to-market at March 31, 2015:		(35,571	)		(87,153	)
	Transfers out of Level 3 upon conversion or payoff of notes payable		—			(230,999	)
	Balance, March 31, 2015	$	114,349		$	541,777
	Net Gain for the period included in earnings relating to the
	liabilities held at March 31, 2015	$	35,571		$	87,153

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
	Employees
Significant Accounting Policies (Textual)
Deferred revenue	$39,233
Allowance for doubtful accounts	0		0
Percentage of ownership in new entity	33.00%
Number of fully diluted shares outstanding	626,644,025	498,696,292
Revenues from the sale of products and services	489,557	392,174
Research and development expense	50,145	9,857
Number of full time employees	4
Key personnel and consultants description	The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants.
Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Number of customers accounted for revenue	2
Stock Options [Member]
Significant Accounting Policies (Textual)
Option outstanding to purchase common stock	73,900,497		66,925,209	23,912,943
Options vested	31,789,510
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage	55.00%	55.00%
Number of customer accounted for accounts receivable	3	2
Accounts Receivable [Member] | Customer One [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage	16.00%	38.00%
Accounts Receivable [Member] | Customer Two [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage	16.00%	17.00%
Accounts Receivable [Member] | Customer Three [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage	23.00%
Sales Revenue Goods and Services Net [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Revenues from the sale of products and services	$322,572
Sales Revenue Goods and Services Net [Member] | Customer One [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Revenues from sale of products and services percentage	17.00%
Sales Revenue Goods and Services Net [Member] | Customer Two [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Revenues from sale of products and services percentage	10.00%

Going_Concern_Matters_Details

Going Concern Matters (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Going Concern Matters (Textual)
Operating loss	($1,048,217)	$677,440
Net cash used in operating activities	-384,251	-257,762
Working capital deficit	$11,000,000

Investments_Details

Investments (Details) (USD $)	3 Months Ended	12 Months Ended	187 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Investments Textual [Abstract]
Ownership percentage	33.00%		33.00%
Cash and expenses paid	$5,000
Income/ loss from equity investment	3,966
Carrying value of the investment	49,563	40,597	49,563
U.S. Stem Cell Clinic, LLC [Member]
Investments Textual [Abstract]
Ownership percentage	33.00%		33.00%
Cash and expenses paid	54,714	54,714
Percentage of income earned	33.00%
Income/ loss from equity investment	3,966		5,151
Carrying value of the investment	$49,563		$49,563

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of property and equipment
Laboratory and medical equipment	$353,252	$352,358
Furniture, fixtures and equipment	125,634	125,634
Computer equipment	47,647	47,647
Leasehold improvements	362,046	362,046
Property and equipment, Gross	888,579	887,685
Less accumulated depreciation and amortization	-876,300	-874,999
Property and equipment, net	$12,279	$12,686

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of accrued expenses
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	$1,571,863	$1,533,217
Interest payable on notes payable	747,141	685,575
Vendor accruals and other	127,114	120,836
Employee commissions, compensation, etc.	14,795	33,987
Accrued expenses, Total	$2,460,913	$2,373,615

Accrued_Expenses_Details_Textu

Accrued Expenses (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accrued Expenses Textual [Abstract]
Recognized gain related to settlement	$59,430	$2,093,632
Common Stock [Member]
Accrued Expenses Textual [Abstract]
Shares issued in conversion of debt		6,750,781
Recognized gain related to settlement		$65,548

Stock_Purchase_Agreement_Detai

Stock Purchase Agreement (Details) (USD $)	1 Months Ended	3 Months Ended	1 Months Ended
	Mar. 19, 2015	Mar. 31, 2015	Oct. 23, 2014	Dec. 31, 2014
Stock Purchase Agreement (Textual)
Common stock value		$670,535		$581,433
Common stock, par value		$0.00		$0.00
Issuance of common stock, Value		59,850
Issuance of common stock, Shares	6,650,000
Common Stock Purchase Agreement [Member]
Stock Purchase Agreement (Textual)
Common stock value			3,000,000
Common stock, par value			$0.00
Agreement term			24 months
Purchase price			$0.00
Purchase price description			The "Initial Purchase Price", is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company's common stock (the "VWAP") during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company's common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
Common stock issued as commitment shares in connection with equity purchase agreement, Shares			12,000,000
Issuance of common stock, Value		$283,578
Issuance of common stock, Shares		35,520,249

Notes_Payable_Details

Notes Payable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 25, 2010
Summary of notes payable
Total notes payable	$1,834,972	$1,870,972
Less unamortized debt discount	-296,365	-339,160
Total notes payable net of unamortized debt discount	1,538,607	1,531,812
Seaside Bank note payable [Member]
Summary of notes payable
Total notes payable	980,000	980,000	980,000	980,000
Hunton & Williams notes payable [Member]
Summary of notes payable
Total notes payable net of unamortized debt discount	384,972	384,972
Asher notes payable [Member]
Summary of notes payable
Total notes payable	190,000
Total notes payable net of unamortized debt discount		151,000
Daniel James management note payable [Member]
Summary of notes payable
Total notes payable	75,000	75,000
Fourth Man, LLC note payable [Member]
Summary of notes payable
Total notes payable	75,000
Total notes payable net of unamortized debt discount		75,000
Magna Group [Member]
Summary of notes payable
Total notes payable	$130,000	$205,000

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Oct. 25, 2010	Jul. 01, 2014	Dec. 31, 2013
Notes Payable (Textual)
Notes payable	$1,834,972		$1,870,972
Effective interest rate					5.00%
Amortization of debt discount	231,795	93,604
Outstanding principal amount			62,500
Magna [Member]
Notes Payable (Textual)
Effective interest rate			12.00%
Outstanding notes payable			75,000
Fair value of embedded derivatives	268,578
Amortization of debt discount	231,795		93,604
Interest expense	88,578
Dividend yield	0.00%
Original interest discount	180,000
Remaining principle balance of notes payable	130,000
Magna [Member] | Maximum [Member]
Notes Payable (Textual)
Expected volatility	116.65%
Risk free rate	0.27%
Expected Term	9 months
Magna [Member] | Minimum [Member]
Notes Payable (Textual)
Expected volatility	112.86%
Risk free rate	0.17%
Expected Term	1 year
Daniel James Management [Member]
Notes Payable (Textual)
Effective interest rate	9.50%
Outstanding notes payable	25,000
Increase in sale percentage	9.50%
Description of note payable	The Daniel Note is convertible into common stock, at holder's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives	35,551
Recorded fair value of derivatives and faire value of each subsequent reporting date	32,972
Outstanding principal amount	25,000
Common stock [Member]
Notes Payable (Textual)
Common stock issued in connection with the conversion of debt, Shares	40,704,366
Seaside Bank note payable [Member]
Notes Payable (Textual)
Notes payable	980,000		980,000	980,000		980,000
Effective interest rate				4.25%
Debt instrument, Maturity date				23-Dec-15
Hunton & Williams notes payable [Member]
Notes Payable (Textual)
Number of outstanding notes payable	2		2
Legal Fees	9,000
Hunton & Williams notes payable [Member] | Note payable one [Member]
Notes Payable (Textual)
Effective interest rate	8.00%		8.00%
Outstanding notes payable	61,150		61,150
Hunton & Williams notes payable [Member] | Note payable two [Member]
Notes Payable (Textual)
Effective interest rate	8.00%		8.00%
Outstanding notes payable	323,822		323,822
Asher notes payable [Member]
Notes Payable (Textual)
Notes payable	190,000
Effective interest rate	8.00%
Debt instrument, Maturity date	26-Dec-15
Outstanding notes payable	75,000
Description of note payable	The Notes are convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives	137,764
Recorded fair value of derivatives and faire value of each subsequent reporting date	124,260
Notes payable, Principle value	114,000
Fourth Man, LLC note payable [Member]
Notes Payable (Textual)
Notes payable	75,000
Effective interest rate	9.50%
Debt instrument, Maturity date	28-Aug-15		28-Aug-15
Description of note payable	The Notes are convertible into common stock, at Fourth Man's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives	95,263
Recorded fair value of derivatives and faire value of each subsequent reporting date	65,705
Notes payable, Principle value	50,000
Notes payable remaining principle balance	75,000
Outstanding principal amount	$50,000
Fourth Man, LLC note payable [Member] | Maximum [Member]
Notes Payable (Textual)
Effective interest rate	9.50%
Fourth Man, LLC note payable [Member] | Minimum [Member]
Notes Payable (Textual)
Effective interest rate	8.00%

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Notes payable	$1,915,656	$1,971,059
Dr Murphy [Member]
Related Party Transaction [Line Items]
Notes payable	465,240	465,240
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	280,143	331,354
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	375,000	375,000
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	500,000	500,000
Ms. Comella [Member]
Related Party Transaction [Line Items]
Notes payable	$295,273	$299,465

Related_Party_Transaction_Deta

Related Party Transaction (Details Textual) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Oct. 03, 2014

Apr. 02, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 24, 2013

Oct. 01, 2012

Sep. 21, 2012

Aug. 17, 2012

Feb. 28, 2013

Dec. 31, 2012

Mar. 30, 2012

Jul. 01, 2014

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2013

Feb. 29, 2012

Nov. 30, 2012

Jun. 04, 2011

Aug. 01, 2014

Aug. 01, 2013

Related Party Transactions (Textual)

Advances, related party

$148,759

$148,759

Common stock issued in lieu of payment

514,886

274,681

Accrued interest

12,705

12,635

Advances of cash

100,000

Common stock issued as payment,shares

8,771,929

Subordinated debt, related party

1,500,000

1,500,000

Effective interest rate

5.00%

Common stock [Member]

Related Party Transactions (Textual)

Amount issued in conversion of debt

500,000

Shares issued in conversion of debt

6,750,781

Accrued Liabilities [Member]

Related Party Transactions (Textual)

Amount issued in conversion of debt

85,447

Shares issued in conversion of debt

3,915,662

Northstar Biotechnology Group, LLC Promissory Note [Member]

Related Party Transactions (Textual)

Outstanding principal amount of debt

362,000

362,000

544,267

Common stock purchase warrants issued

5,000,000

Series A convertible preferred stock issued in exchange for payments

5,000,000

5,000,000

5,000,000

20,000,000

Common stock issued in exchange for payments

10,000,000

10,000,000

Value of debt outstanding

210,000

210,000

Percentage of revenues to be received as royalty

8.00%

Effective interest rate

12.85%

7.00%

Convertible preferred stock issued for penalty settlement

15,000,000

Fair value for Preferred Stock

274,050

Common Stock, Voting Rights

25 votes

Preferred Stock, Voting Rights

Voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders.

20 votes.

Northstar Biotechnology Group, LLC Promissory Note [Member] | Minimum [Member]

Related Party Transactions (Textual)

Effective interest rate

4.75%

Northstar Biotechnology Group, LLC Promissory Note [Member] | Maximum [Member]

Related Party Transactions (Textual)

Effective interest rate

8.00%

Promissory Note [Member]

Related Party Transactions (Textual)

Repayment terms

The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012,

Officer and Employee [Member]

Related Party Transactions (Textual)

Outstanding principal amount of debt

465,240

Effective interest rate

8.00%

Debt instrument, Maturity date

1-Jan-15

Dr Murphy [Member]

Related Party Transactions (Textual)

Outstanding principal amount of debt

465,240

Effective interest rate

8.00%

Outstanding balance of subordinated notes

100,000

140,000

Mr. Tomas [Member]

Related Party Transactions (Textual)

Outstanding principal amount of debt

500,000,000

280,143

375,000

375,000

Effective interest rate

5.00%

5.00%

Face value of note

500,000

375,000

Outstanding promissory notes

51,211

Ms. Comella [Member]

Related Party Transactions (Textual)

Outstanding principal amount of debt

295,273

Effective interest rate

5.00%

Face value of note

300,000

Outstanding promissory notes

$4,192

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	0 Months Ended	3 Months Ended
	Oct. 01, 2012	Mar. 31, 2015
Reset Warrants [Member]
Derivative Liabilities (Textual)
Fair value of derivative liability		$114,349
Dividend yield		0.00%
Expected volatility		112.86%
Risk free rate		1.71%
Expected Term		7 years 6 months
Loss on change in derivatives		35,571
Common stock purchase warrants issued	15,000,000
Exercise price of warrant	$0.01
Warrants exercisable period	10 years
Convertible Notes Payable [Member]
Derivative Liabilities (Textual)
Fair value of embedded derivatives		541,777
Dividend yield		0.00%
Expected volatility		112.86%
Loss on change in derivatives		$87,153
Fair value of common stock		$0.09
Convertible Notes Payable [Member] | Minimum [Member]
Derivative Liabilities (Textual)
Risk free rate		0.03%
Expected Term		3 months 7 days
Convertible Notes Payable [Member] | Maximum [Member]
Derivative Liabilities (Textual)
Risk free rate		0.26%
Expected Term		1 year

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	1 Months Ended	3 Months Ended
	Mar. 19, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Stockholders' Equity (Textual)
Common stock issued in settlement of accounts payable		$41,782
Common stock issued in settlement of litigation		59,850
Common stock issued in settlement of litigation, Shares	6,650,000
Common stock issued in connection with the conversion of debt		231,727	194,044
Derivative Liability, Current		656,126		741,271
Gain on settlement of accounts payable and accrued expenses		41,507
Common Stock Purchase Agreement [Member]
Stockholders' Equity (Textual)
Common stock issued in settlement of litigation		283,578
Common stock issued in settlement of litigation, Shares		35,520,249
Purchase agreement with Magna Equities [Member]
Stockholders' Equity (Textual)
Common stock issued in settlement of litigation, Shares		1,443,656
Common Stock [Member]
Stockholders' Equity (Textual)
Common stock issued in settlement of accounts payable		4,784
Common stock issued in settlement of accounts payable, Shares		4,783,568
Common stock issued in settlement of litigation		$6,650
Common stock issued in settlement of litigation, Shares		6,650,000
Common stock issued in connection with the conversion of debt, Shares		40,704,366
Purchase of warrants shares issued		1,443,656

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (Stock Options [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Summary of options and activity
Options outstanding, Beginning Balance	66,925,209	23,912,943
Granted, shares	7,000,000	43,148,487
Exercised, Shares
Forfeited/Expired, Shares	-24,712	-136,221
Options outstanding, Ending Balance	73,900,497	66,925,209	23,912,943
Options Exercisable, Shares	31,789,510	24,814,222
Available for grant, Shares	89,500,000	96,500,000
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.06	$0.15	$0.67
Granted, Weighted - Average Exercise Price	$0.01	$0.02
Exercised, Weighted - Average Exercise Price	$0.01	$0.02
Forfeited/Expired, Weighted - Average Exercise Price	$0.71	$5.20
Options outstanding, Weighted - Average Exercise Price, Balance	$0.05	$0.06	$0.15
Options exercisable, Weighted - Average Exercise Price	$0.09	$0.12
Options outstanding, Weighted - Average Remaining Contractual Term (in years)		8 years 10 months 24 days	9 years
Options Granted, Weighted - Average Remaining Contractual Term (in years)	10 years	10 years
Options Exercised, Weighted - Average Remaining Contractual Term (in years)	8 years 9 months 18 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years)	8 years 9 months 18 days

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Options outstanding and exercisable for stock-based payment awards
Options Outstanding, Shares	73,900,497
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 9 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$0.05
Options Exercisable, Shares	31,789,510
Options Exercisable, Weighted-Average Exercise Price	$0.09
$0.00 - $0.70 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.70
Options Outstanding, Shares	73,438,487
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 9 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$0.02
Options Exercisable, Shares	31,327,500
Options Exercisable, Weighted-Average Exercise Price	$0.03
$0.71 - $1.28 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$0.71
Range of Exercise Prices, Maximum	$1.28
Options Outstanding, Shares	125,218
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 2 months 12 days
Options Outstanding, Weighted- Average Exercise Price	$0.83
Options Exercisable, Shares	125,218
Options Exercisable, Weighted-Average Exercise Price	$0.83
$5.25 - $5.67 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$5.25
Range of Exercise Prices, Maximum	$5.67
Options Outstanding, Shares	312,080
Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$5.53
Options Exercisable, Shares	312,080
Options Exercisable, Weighted-Average Exercise Price	$5.53
$7.69 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices	$7.69
Options Outstanding, Shares	24,712
Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 3 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$7.69
Options Exercisable, Shares	24,712
Options Exercisable, Weighted-Average Exercise Price	$7.69

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details 2) (Warrant [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrant [Member]
Summary of warrants and activity
Options outstanding, Beginning Balance	150,564,999	118,078,856
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.17	$0.22
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	6 years 8 months 12 days	6 years 3 months 18 days
Shares, issued	1,443,656	57,582,469
Warrants, Weighted-Average Exercise Price	$0.01	$0.02
Warrants, Weighted Average Remaining Contractual Term (in years)	10 years	8 years 2 months 12 days
Exercised, Shares		-11,918,181
Exercised, Weighted - Average Exercise Price		$0.01
Forfeited/Expired, Shares	-1,233,334	-13,178,145
Forfeited/Expired, Weighted - Average Exercise Price	$0.03	$0.08
Options outstanding, Ending Balance	150,775,321	150,564,999
Options outstanding, Weighted - Average Exercise Price, Balance	$0.17	$0.17
Options outstanding, Weighted - Average Remaining Contractual Term	6 years 6 months	6 years 8 months 12 days
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	6 years 6 months

Stock_Options_and_Warrants_Det3

Stock Options and Warrants (Details 3) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrants outstanding and exercisable
Warrants Outstanding, Shares	150,775,321
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 6 months
Warrants Outstanding, Weighted- Average Exercise Price	$0.17
Warrants Exercisable, Shares	135,855,019
Warrants Exercisable, Weighted-Average Exercise Price	$0.10
0.01 - $0.50 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.01
Range of Exercise Prices, Maximum	$0.50
Warrants Outstanding, Shares	144,526,188
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 6 months
Warrants Outstanding, Weighted- Average Exercise Price	$0.02
Warrants Exercisable, Shares	131,150,336
Warrants Exercisable, Weighted-Average Exercise Price	$0.02
0.52 - $0.68 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.52
Range of Exercise Prices, Maximum	$0.68
Warrants Outstanding, Shares	2,699,675
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 1 month 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.58
Warrants Exercisable, Shares	2,699,675
Warrants Exercisable, Weighted-Average Exercise Price	$0.58
0.70 - $1.62 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.70
Range of Exercise Prices, Maximum	$1.62
Warrants Outstanding, Shares	848,176
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 9 months 18 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.71
Warrants Exercisable, Shares	848,176
Warrants Exercisable, Weighted-Average Exercise Price	$0.71
5.67 - $7.69 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$5.67
Range of Exercise Prices, Maximum	$7.69
Warrants Outstanding, Shares	2,701,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term	7 years 7 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$7.55
Warrants Exercisable, Shares	1,156,832
Warrants Exercisable, Weighted-Average Exercise Price	$7.35

Stock_Options_and_Warrants_Det4

Stock Options and Warrants (Details Textual) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Nov. 03, 2014	Feb. 28, 2015
Stock Options and Warrants (Textual)
Fair value of the option vested	$196,966	$194,564
Board of Directors Chairman [Member]
Stock Options and Warrants (Textual)
Options to purchase of common stock shares			2,800,000	7,000,000
Granted, Weighted - Average Exercise Price				$0.01
Stock option vesting period				10 years
Fair value of the option vested				$121,735
Dividend yield				0.00%
Volatility				142.65%
Risk free rate				1.68%

Commiments_and_Contingencies_D

Commiments and Contingencies (Details) (USD $)	1 Months Ended	0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 19, 2015	Nov. 10, 2014
Commiments and Contingencies (Textual)
Common stock issued in settlement of litigation, Shares	6,650,000
Damages of interest		$2.30

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Total (gains) losses
Balance	$656,126
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2015	122,724	-489,371
Warrant [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance	149,920	146,855	146,855
Total (gains) losses
Initial fair value of debt derivative at note issuance
Initial fair value of derivative relating to reset warrants
Mark-to-market	-35,571		3,065
Transfers out of Level 3 upon increase in authorized shares
Transfers out of Level 3 upon conversion or payoff of notes payable
Balance	114,349		149,920
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2015	35,571
Derivative [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance	591,351	256,956	256,956
Total (gains) losses
Initial fair value of debt derivative at note issuance	268,578		1,443,708
Initial fair value of derivative relating to reset warrants
Mark-to-market	-87,153		-429,018
Transfers out of Level 3 upon increase in authorized shares
Transfers out of Level 3 upon conversion and settlement of notes			-680,295
Transfers out of Level 3 upon conversion or payoff of notes payable	-230,999
Balance	541,777		591,351
Net (Loss) Gain for the period included in earnings relating to the liabilities held at March 31, 2015	$87,153

Fair_Value_Measurement_Details1

Fair Value Measurement (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015
Fair Value Measurement (Textual)
Derivative liability		$656,126
Percentage of stock price increase	15.00%

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended
	Oct. 03, 2014	Apr. 02, 2014	Mar. 19, 2015	Mar. 31, 2015	Nov. 03, 2014	Feb. 28, 2015	Apr. 30, 2015	Jan. 28, 2015	Feb. 19, 2015	Apr. 13, 2015	Apr. 27, 2015
Subsequent Event [Line Items]
Accrued interest	$12,705	$12,635
Common stock issued from equity drawdown	514,886	274,681
Issuance of common stock, Shares			6,650,000
Common stock issued in settlement of litigation				59,850
Board of Directors [Member]
Subsequent Event [Line Items]
Options to purchase of common stock shares					2,800,000	7,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Settlement of accured payable							213,904
Common stock issued for services, Shares							6,869,151
Common shares issued in conversion of debt							22,053,009
Amount issued in conversion of debt							79,000
Accrued interest							2,739
Common stock issued							540,736
Issuance of common stock, Shares							5,000
Common stock issued in settlement of litigation							213,904
Issuance of warrants for common stock							540,736
Warrants Term							5 years
Warrant exercise price							$0.01
Note conversion, description							The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on April 26, 2016. The Note is convertible into common stock, at Asher's option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.
Subsequent Event [Member] | Fourth Man, LLC [Member]
Subsequent Event [Line Items]
Debt instrument, Maturity date								26-Apr-16
Subsequent Event [Member] | Vis Vires Group [Member]
Subsequent Event [Line Items]
Convertible Debt										33,000
Interest rate										8.00%
Debt instrument, Maturity date									23-Nov-15
Note conversion, description							The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on January 16, 2016. The Note is convertible into common stock, at Vis's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owed multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
Subsequent Event [Member] | Northstar Biotechnology Group Llc Promissory Note [Member]
Subsequent Event [Line Items]
Accrued interest							12,635
Common stock issued							14,917,086
Common stock issued from equity drawdown							79,075
Issuance of common stock, Shares							1,363,031
Common stock issued in settlement of litigation							413,289
Subsequent Event [Member] | Daniel James Management [Member]
Subsequent Event [Line Items]
Convertible Debt											$25,000
Interest rate											9.50%